PURPOSE We determined the effectiveness of 2 methods to treat overactive bladder in children using intragroup and intergroup comparisons in a randomized clinical trial. MATERIALS AND METHODS Nine boys and 19 girls with a mean ± SD age of 6.4 ± 2.18 years were randomly divided into group 1-parasacral transcutaneous electrical stimulation with placebo drug and group 2-oxybutynin with sham scapu...

The synthesis of 16-electron complexes of the type (Cy-PSiP)RuX(L) (Cy-PSiP = κ3-(2-Cy2PC6H4)2SiMe) is reported. Treatment of (Cy-PSiP)H with one equiv. RuCl2(PPh3)3 in the presence of Et3N afforded a mixture of (Cy-PSiP)RuCl(PPh3) (1) and [(Cy-PSiP)RuCl]2 (2), which exists in a temperature-dependent equilibrium process involving reversible dissociation of PPh3 from 1 to form 2. While treatment...

OBJECTIVES To determine the cognitive and functional consequences of dual use of cholinesterase inhibitors (ChIs) and the bladder anticholinergics oxybutynin or tolterodine. DESIGN Prospective cohort study. SETTING Nursing homes (NHs) in the state of Indiana. PARTICIPANTS Three thousand five hundred thirty-six Medicaid-eligible NH residents aged 65 and older taking a ChI between January 1...

The anticholinergics tolterodine and oxybutynin are well established in the management of overactive bladder. However, their activity at muscarinic receptors distant from the target site (i.e., bladder) produces anticholinergic side effects leading to poor tolerability. In 2004, trospium, solifenacin, and darifenacin were approved by the U.S. Food and Drug Administration for the treatment of ov...

Study selection Randomised or quasi-randomised controlled trials in adults with symptomatic diagnosis of overactive bladder syndrome, urodynamic diagnosis of detrusor overactivity, or both, that compared an anticholinergic drug (given to decrease symptoms of overactive bladder) with placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine chloride, oxybut...

BACKGROUND Overactive bladder (OAB) affects the lives of millions of people worldwide and antimuscarinics are the pharmacological treatment of choice. Meta-analyses of all currently used antimuscarinics for treating OAB found similar efficacy, making the choice dependent on their adverse event profiles. However, conventional meta-analyses often fail to quantify and compare adverse events across...